Published in J Allergy Clin Immunol on April 02, 2013
Techniques of assessing small airways dysfunction. Eur Clin Respir J (2014) 0.94
Small airways dysfunction in asthma: evaluation and management to improve asthma control. Allergy Asthma Immunol Res (2014) 0.92
Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids. Allergy Asthma Immunol Res (2017) 0.81
Effect of gastroesophageal reflux disease on disease severity and characteristics of lung functional changes in patients with asthma. J Cardiovasc Thorac Res (2014) 0.78
Development of a tool to recognize small airways dysfunction in asthma (SADT). Health Qual Life Outcomes (2014) 0.76
Ventilation heterogeneity is increased in patients with chronic heart failure. Physiol Rep (2015) 0.76
Methacholine-Induced Variations in Airway Volume and the Slope of the Alveolar Capnogram Are Distinctly Associated with Airflow Limitation and Airway Closure. PLoS One (2015) 0.75
Multiple breath nitrogen washout profiles in asthmatic patients: what do they mean clinically? J Allergy Clin Immunol (2013) 0.75
Small airway dysfunction and bronchial asthma control : the state of the art. Asthma Res Pract (2015) 0.75
The effect of gas exchange on multiple-breath nitrogen washout measures of ventilation inhomogeneity in the mouse. J Appl Physiol (1985) (2014) 0.75
Myofibroblasts are increased in the lung parenchyma in asthma. PLoS One (2017) 0.75
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res (2006) 4.95
Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Consensus statement for inert gas washout measurement using multiple- and single- breath tests. Eur Respir J (2013) 3.34
Physiology of obesity and effects on lung function. J Appl Physiol (1985) (2009) 3.27
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol (2013) 3.24
Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N Engl J Med (2004) 3.13
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol (2005) 2.77
Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol (2011) 2.38
Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park) (2009) 2.28
The Cancer Genome Atlas: clinical applications for breast cancer. Oncology (Williston Park) (2013) 2.19
US breast cancer mortality trends in young women according to race. Cancer (2014) 2.07
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics (2012) 2.01
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res (2009) 2.01
Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet (2002) 1.98
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79
Quantitative assessment of airway remodeling using high-resolution CT. Chest (2002) 1.79
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol (2009) 1.64
Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther (2004) 1.63
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res (2011) 1.56
Renal transplant imaging using magnetic resonance angiography with a nonnephrotoxic contrast agent. Transplantation (2013) 1.54
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res (2012) 1.52
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat (2006) 1.51
FEV1/FEV6 and FEV6 as an alternative for FEV1/FVC and FVC in the spirometric detection of airway obstruction and restriction. Chest (2005) 1.51
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest (2012) 1.49
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res (2012) 1.47
Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol (2010) 1.47
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg (2009) 1.46
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46
Mechanism underlying accelerated arterial oxygen desaturation during recurrent apnea. Am J Respir Crit Care Med (2010) 1.45
Outcomes in kidney transplant recipients from older living donors. Transplantation (2015) 1.42
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A (2009) 1.42
A clinical comparison between traditional planar V/Q images and planar images generated from SPECT V/Q scintigraphy. Nucl Med Commun (2008) 1.41
Smooth muscle in the maintenance of increased airway resistance elicited by methacholine in humans. Am J Respir Crit Care Med (2014) 1.41
Evidence of an acinar response following treatment for exacerbation in adult patients with cystic fibrosis. Respiration (2014) 1.38
Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat (2009) 1.28
Early detection of COPD: a case finding study in general practice. Respir Med (2006) 1.27
The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol Cell Endocrinol (2011) 1.23
Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer (2011) 1.19
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J Clin Oncol (2010) 1.17
Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway inflammation. Thorax (2007) 1.14
House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med (2009) 1.10
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat (2013) 1.10
Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies. J Allergy Clin Immunol (2011) 1.10
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat (2012) 1.10
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat (2011) 1.10
A comparison of airway and serum matrix metalloproteinase-9 activity among normal subjects, asthmatic patients, and patients with asthmatic mucus hypersecretion. Chest (2005) 1.06
Airway distensibility in adults with asthma and healthy adults, measured by forced oscillation technique. Am J Respir Crit Care Med (2007) 1.05
Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat (2012) 1.05
A model analysis of arterial oxygen desaturation during apnea in preterm infants. PLoS Comput Biol (2009) 1.03
Tracheal stenosis: a flow dynamics study. J Appl Physiol (1985) (2006) 1.02
Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Mol Cancer Ther (2013) 1.02
Allergen-related approaches to immunotherapy. Pharmacol Ther (2008) 1.02
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol (2010) 1.01
Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin Oncol (2006) 1.01
A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer. Breast Cancer Res Treat (2010) 1.00
Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest (2014) 1.00
Allergic rhinitis and its impact on asthma update (ARIA 2008)--western and Asian-Pacific perspective. Asian Pac J Allergy Immunol (2009) 0.99
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat (2013) 0.99
Barriers to delivering asthma care: a qualitative study of general practitioners. Med J Aust (2005) 0.99
Asthma in the elderly. Asia Pac Allergy (2012) 0.99
Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol (2010) 0.98
The effector T cell response to ryegrass pollen is counterregulated by simultaneous induction of regulatory T cells. J Immunol (2010) 0.98
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway. Breast Cancer Res (2005) 0.98
ADAM33 haplotypes are associated with asthma in a large Australian population. Eur J Hum Genet (2006) 0.97
Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. Radiat Oncol (2012) 0.97
Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res (2011) 0.95
The relationship between airflow obstruction, emphysema extent, and small airways function in COPD. Chest (2012) 0.95
Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinol (2014) 0.94
Obesity, expiratory flow limitation and asthma symptoms. Pulm Pharmacol Ther (2012) 0.94
The activin A antagonist follistatin inhibits asthmatic airway remodelling. Thorax (2012) 0.94
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res (2011) 0.94
Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat (2013) 0.93
Inhaled steroids--too much of a good thing? Med J Aust (2003) 0.93
Functional regulatory T cells and allergen immunotherapy. Curr Opin Allergy Clin Immunol (2010) 0.91
Dramatic response of choroidal metastases from breast cancer to a combination of trastuzumab and vinorelbine. Breast J (2004) 0.90
The peanut allergy epidemic: allergen molecular characterisation and prospects for specific therapy. Expert Rev Mol Med (2007) 0.90
Successful targeting of ErbB2 receptors-is PTEN the key? Cancer Cell (2004) 0.89
Patients' views of the burden of asthma: a qualitative study. Med J Aust (2002) 0.89
Modeling airway resistance dynamics after tidal and deep inspirations. J Appl Physiol (1985) (2004) 0.88
Back for more: a qualitative study of emergency department reattendance for asthma. Med J Aust (2004) 0.88
Molecular pathways: extracting medical knowledge from high-throughput genomic data. Clin Cancer Res (2013) 0.88
Molecular profiling of triple negative breast cancer. Breast Dis (2010) 0.88
A 'Good' muscle in a 'Bad' environment: the importance of airway smooth muscle force adaptation to airway hyperresponsiveness. Respir Physiol Neurobiol (2011) 0.88
Effects of methacholine on small airway function measured by forced oscillation technique and multiple breath nitrogen washout in normal subjects. Respir Physiol Neurobiol (2005) 0.87
Neoadjuvant endocrine therapy for breast cancer: more questions than answers. J Clin Oncol (2005) 0.87
Potential food allergens in wine: double-blind, placebo-controlled trial and basophil activation analysis. Nutrition (2006) 0.87